Prof. Laurence Albiges joined us at ESMO 2023 to share her views on the latest renal cell carcinoma (RCC) data presented at the congress. She reviewed data from the following studies:

  • LBA87 - Phase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
  • LBA88 - Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomised open-label phase 3 LITESPARK-005 study
  • 1881O - Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomised phase 2 LITESPARK-013 study
  • 1882O - RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomised, open-label, phase 3 study
  • 1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
  • 1884MO - Phase 2 study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study

 

Watch her video update and download the accompanying slides for a detailed summary.

 

Clinical Takeaways

  • LITESPARK-003/005/013: belzutifan plus cabozantinib appears to improve outcomes in first and subsequent-line settings. Belzutifan monotherapy improves outcomes after IO or VEGFR TKI therapies in previously treated mRCC
  • MEDI5752: Volrustomig monotherapy is active in treatment-naïve aRCC and has the potential to improve outcomes
  • TIDE-A: Shows that VEGFR-TKI discontinuation is safe for selected mRCC patients with evidence of response to VEGFR-TKI+IO combinations in 1st line
  • RENOTORCH: As a significant number of RCC patients live in China, the RENOTORCH trial is expected to be practice-changing for a large population of patients with advanced RCC worldwide

 

  • Help physicians translate the latest renal cell carcinoma data from ESMO 2023 into clinical practice

Professor Laurence Albiges is a medical oncologist and head of the Department of Oncology at Gustave Roussy.

Her main areas of interest are new therapies for metastatic kidney cancer and rare forms of renal cell carcinoma. She is currently developing translational research programs on these topics. Laurence Albiges is the author of numerous publications in recognized scientific journals. She is associate editor of the journal European Urology Oncology.

As a result of her research work, she has received several distinctions, awards and funding, including the Conquer Cancer Foundation Merit Award at the ASCO Genitourinary Symposium in 2015 and the Unicancer-Fondation de France grant. Her research on biomarkers of response to immunotherapy is funded by a K-RTP award.

Prof. Laurence Albiges is a member of the GETUG steering committee and of the EAU (European Association of Urology) guidelines panel for kidney cancer. She is involved in the ESMO (European Society for Medical Oncology) where she has been a member of the scientific committee of the congress since 2017. She belongs to the cancer committee of the French association of urology. She belongs to the scientific board of the EIKCS (European International Kidney Cancer Symposium) and EMUC (European Multidisciplinary Congress on Urological Cancers). She is a member of the scientific board of the KCA (Kidney Cancer Association).

Prof. Laurence Albiges has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, BMS, Eisai, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Eisai Europe Limited.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

2

of 3

episode
Oncology 
Câncer de Pulmão: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 2 da série de podcasts em vídeo de 3 partes

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.